BRPI0411098A - benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos - Google Patents
benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticosInfo
- Publication number
- BRPI0411098A BRPI0411098A BRPI0411098-6A BRPI0411098A BRPI0411098A BR PI0411098 A BRPI0411098 A BR PI0411098A BR PI0411098 A BRPI0411098 A BR PI0411098A BR PI0411098 A BRPI0411098 A BR PI0411098A
- Authority
- BR
- Brazil
- Prior art keywords
- therapeutic agents
- benzofuranocarboxamides
- pi3k activity
- diseases
- formula
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 108091007960 PI3Ks Proteins 0.000 abstract 1
- 201000011529 cardiovascular cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000001907 coumarones Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
"BENZOFURANOCARBOXAMIDAS, COM ATIVIDADE PI3K, COMO AGENTES TERAPêUTICOS". A presente invenção refere-se a benzofuranos de Fórmula (I): em que R¬ 1¬, R¬ 2¬, R¬ 3¬, e L têm qualquer um dos valores definidos para esse fim no relatório descritivo, e sais farmaceuticamente aceitáveis do mesmo, que são úteis como agentes no tratamento de doenças e estados, incluindo doenças inflamatórias, doenças cardiovasculares, e cânceres. São também proporcionadas composições farmacêuticas compreendendo um ou mais compostos de Fórmula (I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47625103P | 2003-06-05 | 2003-06-05 | |
PCT/IB2004/001788 WO2004108709A1 (en) | 2003-06-05 | 2004-05-24 | Tetrazol benzofurancarboxamides with p13k aktivity as therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0411098A true BRPI0411098A (pt) | 2006-07-18 |
Family
ID=33511768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0411098-6A BRPI0411098A (pt) | 2003-06-05 | 2004-05-24 | benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos |
Country Status (7)
Country | Link |
---|---|
US (1) | US20050020631A1 (pt) |
EP (1) | EP1644364A1 (pt) |
JP (1) | JP2006526608A (pt) |
BR (1) | BRPI0411098A (pt) |
CA (1) | CA2527934A1 (pt) |
MX (1) | MXPA05012894A (pt) |
WO (1) | WO2004108709A1 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
US8906894B1 (en) * | 2000-07-27 | 2014-12-09 | Thomas N. Thomas | Methods for preventing and treating thrombotic disorders |
US20050054614A1 (en) * | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
WO2005016348A1 (en) * | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
FR2862646B1 (fr) * | 2003-11-20 | 2006-02-24 | Merck Sante Sas | Nouveaux composes antidiabetiques contenant des derives benzofuranes, benzothiophenes |
JP2007530654A (ja) * | 2004-03-30 | 2007-11-01 | ファイザー・プロダクツ・インク | シグナル伝達阻害剤の組合せ |
ES2605792T3 (es) | 2004-05-13 | 2017-03-16 | Icos Corporation | Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana |
JP2008500338A (ja) * | 2004-05-25 | 2008-01-10 | イコス・コーポレイション | 造血細胞の異常増殖を治療及び/又は予防する方法 |
EP1885356A2 (en) * | 2005-02-17 | 2008-02-13 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
NZ592880A (en) | 2008-11-13 | 2013-06-28 | Gilead Calistoga Llc | Combinations of purine derivatives and proteasome inhibitors such as bortezomib for the treatment of hematological malignancy |
US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
CA2756347A1 (en) | 2009-03-24 | 2010-09-30 | Gilead Calistoga Llc | Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
WO2010123931A1 (en) | 2009-04-20 | 2010-10-28 | Calistoga Pharmaceuticals Inc. | Methods of treatment for solid tumors |
JP2013500257A (ja) | 2009-07-21 | 2013-01-07 | ギリアード カリストガ エルエルシー | Pi3kインヒビターでの肝障害の処置 |
US8637557B2 (en) | 2009-10-19 | 2014-01-28 | Taisho Pharmaceutical Co., Ltd | Aminothiazole derivative |
PL223225B1 (pl) * | 2012-02-21 | 2016-10-31 | Centrum Badań Molekularnych i Makromolekularnych Polskiej Akademii Nauk | Halogenopochodne benzo[b]furanów, ewentualnie w postaci farmaceutycznie dopuszczalnej soli oraz zastosowanie halogenopochodnych benzo[b]furanów |
AP2014007875A0 (en) | 2012-03-05 | 2014-08-31 | Gilead Calistoga Llc | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
MX2016008259A (es) | 2013-12-20 | 2016-10-13 | Gilead Calistoga Llc | Metodo de proceso para inhibidores de fosfatidilinositol 3-cinasa. |
US9708327B2 (en) | 2013-12-20 | 2017-07-18 | Gilead Calistoga Llc | Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
MX2016016530A (es) | 2014-06-13 | 2017-03-27 | Gilead Sciences Inc | Inhibidores de fosfatidilinositol 3-quinasa. |
US11351156B2 (en) | 2017-10-13 | 2022-06-07 | Inserm | Combination treatment of pancreatic cancer |
EP3713963A1 (en) | 2017-11-23 | 2020-09-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A new marker for predicting the sensitivity to pi3k inhibitors |
EP4334298A1 (en) | 2021-06-14 | 2024-03-13 | Scorpion Therapeutics, Inc. | Urea derivatives which can be used to treat cancer |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3954748A (en) * | 1968-07-29 | 1976-05-04 | Societe D'etudes Scientifiques Et Industrielles De L'ile-De-France | 3-Alkoxy-thianapthene-2-carboxamides |
US4703053A (en) * | 1985-10-28 | 1987-10-27 | Warner-Lambert Company | Benzothiophenes and benzofurans and antiallergic use thereof |
IE58555B1 (en) * | 1984-12-10 | 1993-10-06 | Warner Almbert Company | Novel benzothiophenes and benzofurans having antiallergy activity |
US4800211A (en) * | 1986-08-18 | 1989-01-24 | Merck & Co., Inc. | 5-methylthio-3-hydroxybenzo [b]thiophene-2-carboxamide derivatives as cyclooxygenase and lipoxygenase inhibitors |
US4767776A (en) * | 1987-02-20 | 1988-08-30 | Warner-Lambert Company | N-1H-tetrazol-5-yl-2-naphthalene carboxamides and their use as antiallergy and antiinflammatory agents |
US4764525A (en) * | 1987-02-25 | 1988-08-16 | Warner-Lambert Company | N-1H-tetrazol-5-ylbenzamides having use as antiallergy and antiinflammatory agents |
US4931459A (en) * | 1987-07-14 | 1990-06-05 | Warner-Lambert Company | Method for treating acute respirator distress syndrome |
US4910317A (en) * | 1987-07-14 | 1990-03-20 | Warner-Lambert Company | Benzofurans and benzothiophenes having antiallergic activity and method of use thereof |
EP0548250B1 (en) * | 1990-09-10 | 1996-03-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Substituted bicyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity |
US5208253A (en) * | 1992-02-24 | 1993-05-04 | Warner-Lambert Company | 3-alkyloxy-, aryloxy-, or arylalkyloxy-benzo(b) thiophene-2-carboxamides as inhibitors of cell adhesion |
US5426113A (en) * | 1994-04-08 | 1995-06-20 | Warner-Lambert Company | Method of preventing ulcer formation caused by nonsteroidal antiinflammatory drugs employing tetrazol-benzothiophene carboxamide compounds |
HRP950288A2 (en) * | 1994-05-31 | 1997-08-31 | Bayer Ag | Oxalylamino-benzofuran- and benzothienyl-derivatives |
US5731317A (en) * | 1995-03-10 | 1998-03-24 | Merck & Co., Inc. | Bridged piperidines promote release of growth hormone |
WO1997009056A1 (fr) * | 1995-09-07 | 1997-03-13 | L'oreal | Extrait d'iridacees et compositions le contenant |
DE19911165B4 (de) * | 1999-03-12 | 2008-03-13 | Bayer Cropscience Ag | Entlaubungsmittel |
AR022889A1 (es) * | 1999-03-12 | 2002-09-04 | Bayer Cropscience Ag | Agente desfoliante |
ATE551325T1 (de) * | 2000-01-24 | 2012-04-15 | Astrazeneca Ab | Therapeutische morpholino-substituierte verbindungen |
-
2004
- 2004-05-24 EP EP04734569A patent/EP1644364A1/en not_active Withdrawn
- 2004-05-24 JP JP2006508422A patent/JP2006526608A/ja not_active Abandoned
- 2004-05-24 MX MXPA05012894A patent/MXPA05012894A/es not_active Application Discontinuation
- 2004-05-24 BR BRPI0411098-6A patent/BRPI0411098A/pt not_active IP Right Cessation
- 2004-05-24 CA CA002527934A patent/CA2527934A1/en not_active Abandoned
- 2004-05-24 WO PCT/IB2004/001788 patent/WO2004108709A1/en active Application Filing
- 2004-06-03 US US10/860,527 patent/US20050020631A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1644364A1 (en) | 2006-04-12 |
JP2006526608A (ja) | 2006-11-24 |
WO2004108709A1 (en) | 2004-12-16 |
US20050020631A1 (en) | 2005-01-27 |
MXPA05012894A (es) | 2006-02-22 |
CA2527934A1 (en) | 2004-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0411098A (pt) | benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos | |
BRPI0417771A (pt) | heterociclos azabicìclicos como moduladores de receptor canabinóides | |
BRPI0410913A (pt) | benzotiofenos substituìdos com cicloalquil e heterocicloalquil como agentes terapêuticos | |
BRPI0417820A (pt) | heterociclos azabicìclicos como moduladores de receptor canabinóide | |
BR0317572A (pt) | Benzoxazinas e seus derivados como inibidores de pi3ks | |
BRPI0408005A (pt) | composto, composição farmacêutica, métodos para inibir angiogênese, atividade de pde4 em uma célula e proliferação de célula de cáncer, para inibir ou reduzir polimerização de tubulina ou estabilidade de tubulina em uma célula, para tratar ou melhorar um distúrbio inflamatório, um cáncer e um distúrbio do sistema nervoso central e para visar, bloquear ou destruir a função de vasculatura de tumor e o endotélio de vasos de tumor | |
BRPI0914902B8 (pt) | Composição farmacêutica para uso no tratamento de mal de parkinson | |
BRPI0506977A (pt) | composto de tetrahidrocarbolina como agentes anticáncer | |
EA200700362A1 (ru) | Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью | |
BR0316386A (pt) | Benzoxazin-3-onas e seus derivados como inibidores de p13k | |
BRPI0416656A (pt) | compostos de pirrolopirimidina úteis no tratamento do cáncer | |
BRPI0811280B8 (pt) | compostos amino-heterocíclicos, composição farmacêutica que os compreende e usos dos referidos compostos | |
BR122019010200B8 (pt) | compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas | |
ATE452129T1 (de) | N-phenyl-2-pyrimidine-amine derivatives | |
DK1819227T3 (da) | Farmaceutisk formulering af decitabin | |
NO20064186L (no) | Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod | |
BRPI0508540A (pt) | composto, composição farmacêutica, e, uso de um composto | |
BRPI0410649A (pt) | benzo(b) tiofeno 3-arilóxi e 3-heteroarilóxi substituìdos como agentes terapêuticos com atividade pi3k | |
BRPI0411017A (pt) | indóis 3-substituìdos e derivados dos mesmos como agentes terapêuticos | |
BRPI0411092A (pt) | benzo[b]tiofenos substituìdos com 3-arilsulfanila e com 3-heteroarilsulfanila como agentes terapêuticos | |
BR0315580A (pt) | Derivados de metileno uréia | |
BRPI0418099A (pt) | compostos, composição farmacêutica, e uso de um composto | |
BR0210028A (pt) | Agentes antibacterianos | |
SE0401342D0 (sv) | Therapeutic compounds | |
ATE487720T1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |